Malondialdehyde‐Acetaldehyde Adducts and Anti–Malondialdehyde‐Acetaldehyde Antibodies in Rheumatoid Arthritis

Objective Malondialdehyde‐acetaldehyde (MAA) adducts are a product of oxidative stress associated with tolerance loss in several disease states. This study was undertaken to investigate the presence of MAA adducts and circulating anti‐MAA antibodies in patients with rheumatoid arthritis (RA). Method...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 67; no. 3; pp. 645 - 655
Main Authors Thiele, Geoffrey M., Duryee, Michael J., Anderson, Daniel R., Klassen, Lynell W., Mohring, Stephen M., Young, Kathleen A., Benissan‐Messan, Dathe, Sayles, Harlan, Dusad, Anand, Hunter, Carlos D., Sokolove, Jeremy, Robinson, William H., O'Dell, James R., Nicholas, Anthony P., Tuma, Dean J., Mikuls, Ted R.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.03.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objective Malondialdehyde‐acetaldehyde (MAA) adducts are a product of oxidative stress associated with tolerance loss in several disease states. This study was undertaken to investigate the presence of MAA adducts and circulating anti‐MAA antibodies in patients with rheumatoid arthritis (RA). Methods Synovial tissue from patients with RA and patients with osteoarthritis (OA) were examined for the presence of MAA‐modified and citrullinated proteins. Anti‐MAA antibody isotypes were measured in RA patients (n = 1,720) and healthy controls (n = 80) by enzyme‐linked immunosorbent assay. Antigen‐specific anti–citrullinated protein antibodies (ACPAs) were measured in RA patients using a multiplex antigen array. Anti‐MAA isotype concentrations were compared in a subset of RA patients (n = 80) and matched healthy controls (n = 80). Associations of anti‐MAA antibody isotypes with disease characteristics, including ACPA positivity, were examined in all RA patients. Results Expression of MAA adducts was increased in RA synovial tissue compared to OA synovial tissue, and colocalization with citrullinated proteins was found. Increased levels of anti‐MAA antibody isotypes were observed in RA patients compared to controls (P < 0.001). Among RA patients, anti‐MAA antibody isotypes were associated with seropositivity for ACPAs and rheumatoid factor (P < 0.001) in addition to select measures of disease activity. Higher anti‐MAA antibody concentrations were associated with a greater number of positive antigen‐specific ACPA analytes (expressed at high titer) (P < 0.001) and a higher ACPA score (P < 0.001), independent of other covariates. Conclusion MAA adduct formation is increased in RA and appears to result in robust antibody responses that are strongly associated with ACPAs. These results support speculation that MAA formation may be a cofactor that drives tolerance loss, resulting in the autoimmune responses characteristic of RA.
AbstractList Objective Malondialdehyde‐acetaldehyde (MAA) adducts are a product of oxidative stress associated with tolerance loss in several disease states. This study was undertaken to investigate the presence of MAA adducts and circulating anti‐MAA antibodies in patients with rheumatoid arthritis (RA). Methods Synovial tissue from patients with RA and patients with osteoarthritis (OA) were examined for the presence of MAA‐modified and citrullinated proteins. Anti‐MAA antibody isotypes were measured in RA patients (n = 1,720) and healthy controls (n = 80) by enzyme‐linked immunosorbent assay. Antigen‐specific anti–citrullinated protein antibodies (ACPAs) were measured in RA patients using a multiplex antigen array. Anti‐MAA isotype concentrations were compared in a subset of RA patients (n = 80) and matched healthy controls (n = 80). Associations of anti‐MAA antibody isotypes with disease characteristics, including ACPA positivity, were examined in all RA patients. Results Expression of MAA adducts was increased in RA synovial tissue compared to OA synovial tissue, and colocalization with citrullinated proteins was found. Increased levels of anti‐MAA antibody isotypes were observed in RA patients compared to controls (P < 0.001). Among RA patients, anti‐MAA antibody isotypes were associated with seropositivity for ACPAs and rheumatoid factor (P < 0.001) in addition to select measures of disease activity. Higher anti‐MAA antibody concentrations were associated with a greater number of positive antigen‐specific ACPA analytes (expressed at high titer) (P < 0.001) and a higher ACPA score (P < 0.001), independent of other covariates. Conclusion MAA adduct formation is increased in RA and appears to result in robust antibody responses that are strongly associated with ACPAs. These results support speculation that MAA formation may be a cofactor that drives tolerance loss, resulting in the autoimmune responses characteristic of RA.
OBJECTIVEMalondialdehyde-acetaldehyde (MAA) adducts are a product of oxidative stress associated with tolerance loss in several disease states. This study was undertaken to investigate the presence of MAA adducts and circulating anti-MAA antibodies in patients with rheumatoid arthritis (RA).METHODSSynovial tissue from patients with RA and patients with osteoarthritis (OA) were examined for the presence of MAA-modified and citrullinated proteins. Anti-MAA antibody isotypes were measured in RA patients (n = 1,720) and healthy controls (n = 80) by enzyme-linked immunosorbent assay. Antigen-specific anti-citrullinated protein antibodies (ACPAs) were measured in RA patients using a multiplex antigen array. Anti-MAA isotype concentrations were compared in a subset of RA patients (n = 80) and matched healthy controls (n = 80). Associations of anti-MAA antibody isotypes with disease characteristics, including ACPA positivity, were examined in all RA patients.RESULTSExpression of MAA adducts was increased in RA synovial tissue compared to OA synovial tissue, and colocalization with citrullinated proteins was found. Increased levels of anti-MAA antibody isotypes were observed in RA patients compared to controls (P < 0.001). Among RA patients, anti-MAA antibody isotypes were associated with seropositivity for ACPAs and rheumatoid factor (P < 0.001) in addition to select measures of disease activity. Higher anti-MAA antibody concentrations were associated with a greater number of positive antigen-specific ACPA analytes (expressed at high titer) (P < 0.001) and a higher ACPA score (P < 0.001), independent of other covariates.CONCLUSIONMAA adduct formation is increased in RA and appears to result in robust antibody responses that are strongly associated with ACPAs. These results support speculation that MAA formation may be a cofactor that drives tolerance loss, resulting in the autoimmune responses characteristic of RA.
Malondialdehyde-acetaldehyde (MAA) adducts are a product of oxidative stress associated with tolerance loss in several disease states. This study was undertaken to investigate the presence of MAA adducts and circulating anti-MAA antibodies in patients with rheumatoid arthritis (RA). Synovial tissue from patients with RA and patients with osteoarthritis (OA) were examined for the presence of MAA-modified and citrullinated proteins. Anti-MAA antibody isotypes were measured in RA patients (n = 1,720) and healthy controls (n = 80) by enzyme-linked immunosorbent assay. Antigen-specific anti-citrullinated protein antibodies (ACPAs) were measured in RA patients using a multiplex antigen array. Anti-MAA isotype concentrations were compared in a subset of RA patients (n = 80) and matched healthy controls (n = 80). Associations of anti-MAA antibody isotypes with disease characteristics, including ACPA positivity, were examined in all RA patients. Expression of MAA adducts was increased in RA synovial tissue compared to OA synovial tissue, and colocalization with citrullinated proteins was found. Increased levels of anti-MAA antibody isotypes were observed in RA patients compared to controls (P < 0.001). Among RA patients, anti-MAA antibody isotypes were associated with seropositivity for ACPAs and rheumatoid factor (P < 0.001) in addition to select measures of disease activity. Higher anti-MAA antibody concentrations were associated with a greater number of positive antigen-specific ACPA analytes (expressed at high titer) (P < 0.001) and a higher ACPA score (P < 0.001), independent of other covariates. MAA adduct formation is increased in RA and appears to result in robust antibody responses that are strongly associated with ACPAs. These results support speculation that MAA formation may be a cofactor that drives tolerance loss, resulting in the autoimmune responses characteristic of RA.
Objective Malondialdehyde-acetaldehyde (MAA) adducts are a product of oxidative stress associated with tolerance loss in several disease states. This study was undertaken to investigate the presence of MAA adducts and circulating anti-MAA antibodies in patients with rheumatoid arthritis (RA). Methods Synovial tissue from patients with RA and patients with osteoarthritis (OA) were examined for the presence of MAA-modified and citrullinated proteins. Anti-MAA antibody isotypes were measured in RA patients (n = 1,720) and healthy controls (n = 80) by enzyme-linked immunosorbent assay. Antigen-specific anti-citrullinated protein antibodies (ACPAs) were measured in RA patients using a multiplex antigen array. Anti-MAA isotype concentrations were compared in a subset of RA patients (n = 80) and matched healthy controls (n = 80). Associations of anti-MAA antibody isotypes with disease characteristics, including ACPA positivity, were examined in all RA patients. Results Expression of MAA adducts was increased in RA synovial tissue compared to OA synovial tissue, and colocalization with citrullinated proteins was found. Increased levels of anti-MAA antibody isotypes were observed in RA patients compared to controls (P < 0.001). Among RA patients, anti-MAA antibody isotypes were associated with seropositivity for ACPAs and rheumatoid factor (P < 0.001) in addition to select measures of disease activity. Higher anti-MAA antibody concentrations were associated with a greater number of positive antigen-specific ACPA analytes (expressed at high titer) (P < 0.001) and a higher ACPA score (P < 0.001), independent of other covariates. Conclusion MAA adduct formation is increased in RA and appears to result in robust antibody responses that are strongly associated with ACPAs. These results support speculation that MAA formation may be a cofactor that drives tolerance loss, resulting in the autoimmune responses characteristic of RA.
Author Duryee, Michael J.
Benissan‐Messan, Dathe
Hunter, Carlos D.
Young, Kathleen A.
Mikuls, Ted R.
Thiele, Geoffrey M.
Sokolove, Jeremy
Mohring, Stephen M.
Robinson, William H.
Anderson, Daniel R.
Nicholas, Anthony P.
O'Dell, James R.
Tuma, Dean J.
Dusad, Anand
Klassen, Lynell W.
Sayles, Harlan
Author_xml – sequence: 1
  givenname: Geoffrey M.
  surname: Thiele
  fullname: Thiele, Geoffrey M.
  organization: VA Nebraska–Western Iowa Health Care System, Omaha, Nebraska, and University of Nebraska Medical Center
– sequence: 2
  givenname: Michael J.
  surname: Duryee
  fullname: Duryee, Michael J.
  organization: VA Nebraska–Western Iowa Health Care System, Omaha, Nebraska, and University of Nebraska Medical Center
– sequence: 3
  givenname: Daniel R.
  surname: Anderson
  fullname: Anderson, Daniel R.
  organization: University of Nebraska Medical Center
– sequence: 4
  givenname: Lynell W.
  surname: Klassen
  fullname: Klassen, Lynell W.
  organization: VA Nebraska–Western Iowa Health Care System, Omaha, Nebraska, and University of Nebraska Medical Center
– sequence: 5
  givenname: Stephen M.
  surname: Mohring
  fullname: Mohring, Stephen M.
  organization: University of Nebraska Medical Center
– sequence: 6
  givenname: Kathleen A.
  surname: Young
  fullname: Young, Kathleen A.
  organization: University of Nebraska Medical Center
– sequence: 7
  givenname: Dathe
  surname: Benissan‐Messan
  fullname: Benissan‐Messan, Dathe
  organization: University of Nebraska Medical Center
– sequence: 8
  givenname: Harlan
  surname: Sayles
  fullname: Sayles, Harlan
  organization: University of Nebraska Medical Center
– sequence: 9
  givenname: Anand
  surname: Dusad
  fullname: Dusad, Anand
  organization: University of Nebraska Medical Center
– sequence: 10
  givenname: Carlos D.
  surname: Hunter
  fullname: Hunter, Carlos D.
  organization: University of Nebraska Medical Center
– sequence: 11
  givenname: Jeremy
  surname: Sokolove
  fullname: Sokolove, Jeremy
  organization: VA Palo Alto Health Care System and Stanford University
– sequence: 12
  givenname: William H.
  surname: Robinson
  fullname: Robinson, William H.
  organization: VA Palo Alto Health Care System and Stanford University
– sequence: 13
  givenname: James R.
  surname: O'Dell
  fullname: O'Dell, James R.
  organization: VA Nebraska–Western Iowa Health Care System, Omaha, Nebraska, and University of Nebraska Medical Center
– sequence: 14
  givenname: Anthony P.
  surname: Nicholas
  fullname: Nicholas, Anthony P.
  organization: University of Alabama at Birmingham
– sequence: 15
  givenname: Dean J.
  surname: Tuma
  fullname: Tuma, Dean J.
  organization: VA Nebraska–Western Iowa Health Care System
– sequence: 16
  givenname: Ted R.
  surname: Mikuls
  fullname: Mikuls, Ted R.
  organization: VA Nebraska–Western Iowa Health Care System, Omaha, Nebraska, and University of Nebraska Medical Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25417811$$D View this record in MEDLINE/PubMed
BookMark eNqF0U9LwzAYBvAgEzfnDn4BKXjRQ7ckbdrkWIb_YCKMeS5p85ZldO1MWmS3fQTBb7hPYuY2D4KYSxL4vQ8hzznqVHUFCF0SPCQY05E0zTDgIhInqEcDGvmMYtY5nokgXTSwdoHdEjGOMDtDXcpCEnNCesg-y7KulJalgvlawXbzkeTQHK9eolSbN9aTlfKSqtHbzed_E05ltdJgPV150zm0S9nU2o2bZm50o-0FOi1kaWFw2Pvo9f5uNn70Jy8PT-Nk4uchC4UfE5UXAYkglJhxBQSUlLkgJMyjsFAZF5TgjANlkjFZhKIgUSEYz1isgDMc9NHNPndl6rcWbJMutc2hLGUFdWtTEjERR4yLwNHrX3RRt6Zyr9upmIeUU-bU7V7lprbWQJGujF5Ks04JTndlpK6M9LsMZ68OiW22BPUjj1_vwGgP3nUJ67-T0mQ620d-AZHzmUY
CitedBy_id crossref_primary_10_1002_art_38970
crossref_primary_10_3389_fimmu_2022_980805
crossref_primary_10_1016_j_jbc_2023_105320
crossref_primary_10_1080_25785826_2018_1556017
crossref_primary_10_1016_j_clim_2024_110303
crossref_primary_10_1371_journal_pone_0230682
crossref_primary_10_1021_acs_analchem_6b05065
crossref_primary_10_3389_fimmu_2023_1203548
crossref_primary_10_1038_nrrheum_2016_151
crossref_primary_10_1016_j_redox_2017_07_018
crossref_primary_10_1111_odi_13936
crossref_primary_10_3390_biology13050331
crossref_primary_10_1111_eci_12858
crossref_primary_10_1016_j_freeradbiomed_2019_08_022
crossref_primary_10_1038_s41584_024_01124_6
crossref_primary_10_1136_rmdopen_2021_002079
crossref_primary_10_3389_fimmu_2023_1221125
crossref_primary_10_3390_ani9090693
crossref_primary_10_1002_art_41074
crossref_primary_10_1172_jci_insight_125278
crossref_primary_10_1021_acs_jafc_8b02241
crossref_primary_10_1038_s41598_019_56279_0
crossref_primary_10_1093_ntr_ntw030
crossref_primary_10_1007_s12016_021_08890_1
crossref_primary_10_3390_ijms22189686
crossref_primary_10_1016_j_intimp_2022_109010
crossref_primary_10_1080_17476348_2022_2089116
crossref_primary_10_1186_s12967_017_1131_x
crossref_primary_10_3390_molecules25173855
crossref_primary_10_1007_s40744_019_00189_0
crossref_primary_10_1186_s12014_023_09411_2
crossref_primary_10_1002_art_40879
crossref_primary_10_1016_j_berh_2018_10_005
crossref_primary_10_1016_j_autrev_2015_03_003
crossref_primary_10_1016_j_jprot_2017_08_012
crossref_primary_10_1038_nrrheum_2017_15
crossref_primary_10_4049_jimmunol_1501021
crossref_primary_10_1016_j_intimp_2018_01_022
crossref_primary_10_1038_s41584_018_0070_0
crossref_primary_10_1186_s13075_023_03180_x
crossref_primary_10_1136_annrheumdis_2016_210772
crossref_primary_10_1016_j_intimp_2020_107260
crossref_primary_10_3390_jcm13030901
crossref_primary_10_1111_imr_12829
crossref_primary_10_1186_s12931_017_0517_x
crossref_primary_10_1152_ajplung_00221_2023
crossref_primary_10_1016_j_berh_2019_101438
crossref_primary_10_1111_imr_12832
crossref_primary_10_1186_s12931_022_02085_8
crossref_primary_10_3390_cells13090743
crossref_primary_10_1097_BOR_0000000000000277
crossref_primary_10_1186_s42358_018_0042_8
crossref_primary_10_3390_ijms22147389
crossref_primary_10_3389_fimmu_2022_1010893
crossref_primary_10_1038_s41420_023_01613_9
crossref_primary_10_1016_j_intimp_2022_109400
crossref_primary_10_1186_s13075_021_02687_5
crossref_primary_10_1186_s13075_023_03009_7
crossref_primary_10_1002_art_41424
crossref_primary_10_1002_art_42916
crossref_primary_10_1007_s40011_023_01518_8
crossref_primary_10_3390_ijms25052688
crossref_primary_10_2139_ssrn_4125936
crossref_primary_10_1080_03009742_2020_1795244
crossref_primary_10_3389_fimmu_2021_685312
crossref_primary_10_3390_biomedicines10061367
crossref_primary_10_3390_ijms19124078
crossref_primary_10_3389_fimmu_2018_03168
crossref_primary_10_1016_j_jaci_2015_10_024
crossref_primary_10_1152_ajpgi_00183_2017
crossref_primary_10_1016_j_jaut_2017_06_004
crossref_primary_10_1016_j_autrev_2021_102797
crossref_primary_10_1016_j_intimp_2021_108069
crossref_primary_10_1155_2016_6097417
crossref_primary_10_1177_20587384211000554
crossref_primary_10_1111_jre_12486
crossref_primary_10_3390_ijms22031185
crossref_primary_10_1186_s12891_016_1067_y
crossref_primary_10_1002_art_40900
crossref_primary_10_1016_j_berh_2020_101497
crossref_primary_10_1186_s12931_017_0703_x
crossref_primary_10_1080_07853890_2020_1724321
crossref_primary_10_1002_pmic_201600104
crossref_primary_10_1136_rmdopen_2023_003480
crossref_primary_10_1371_journal_pone_0215927
crossref_primary_10_1016_j_intimp_2020_106433
crossref_primary_10_1016_j_ebiom_2022_104233
crossref_primary_10_1097_MCP_0000000000000710
crossref_primary_10_1002_jbmr_3745
crossref_primary_10_1016_j_clinbiochem_2022_07_002
crossref_primary_10_1002_JPER_23_0604
crossref_primary_10_3390_ijms222413290
crossref_primary_10_1016_j_autrev_2016_03_003
crossref_primary_10_1016_j_clim_2015_04_005
crossref_primary_10_1038_s41598_017_11289_8
crossref_primary_10_1016_j_jaut_2022_102903
crossref_primary_10_1016_j_berh_2017_08_001
crossref_primary_10_3389_fimmu_2021_627986
crossref_primary_10_1093_rheumatology_kex212
crossref_primary_10_3390_ijms232415803
crossref_primary_10_1038_s41598_017_09657_5
crossref_primary_10_1038_s41598_022_14954_9
crossref_primary_10_1021_acs_jproteome_2c00442
crossref_primary_10_1007_s11926_017_0701_5
crossref_primary_10_1053_j_gastro_2022_06_071
crossref_primary_10_1038_s41415_019_0723_7
crossref_primary_10_1097_BOR_0000000000000356
crossref_primary_10_1111_prd_12432
crossref_primary_10_3390_ijms231810297
crossref_primary_10_1016_j_freeradbiomed_2015_09_003
crossref_primary_10_1016_j_rdc_2020_12_006
crossref_primary_10_3390_biom5042987
crossref_primary_10_3389_fmed_2023_1195747
crossref_primary_10_3390_antiox10010045
Cites_doi 10.3748/wjg.v13.i37.4938
10.1172/JCI117963
10.1093/rheumatology/keq232
10.1016/j.bcp.2005.08.014
10.1016/0003-2697(88)90051-6
10.1111/j.1530-0277.2010.01309.x
10.1111/j.1530-0277.2011.01443.x
10.1002/hep.510230431
10.1111/j.1530-0277.2002.tb02436.x
10.1111/j.1530-0277.2002.tb02520.x
10.1021/tx000222a
10.1111/j.1756-185X.2009.01375.x
10.1021/tx0500676
10.1016/j.intimp.2008.09.008
10.1136/ard.2006.054924
10.1016/j.intimp.2004.04.004
10.1016/S1567-5769(03)00136-X
10.1097/01.ALC.0000148115.90045.C5
10.1002/glia.10039
10.1111/j.1530-0277.1998.tb03973.x
10.1016/j.bbrc.2008.03.140
10.1007/s00296-011-1964-1
10.1002/art.1780380107
10.1172/JCI25422
10.1016/S0006-2952(03)00416-7
10.1186/ar1697
10.1016/j.jbspin.2012.01.008
10.1016/S0021-9150(98)00153-1
10.7150/ijms.8.139
10.1016/j.imbio.2011.04.001
10.1053/he.2000.5373
10.1080/10715760600902302
10.1002/art.1780310302
10.1161/atvb.32.suppl_1.A303
10.1007/s10067-006-0244-z
10.1016/j.freeradbiomed.2010.08.001
10.1007/978-1-59745-242-7_17
10.1073/pnas.091062498
ContentType Journal Article
Copyright Copyright © 2015 by the American College of Rheumatology
Copyright © 2015 by the American College of Rheumatology.
Copyright_xml – notice: Copyright © 2015 by the American College of Rheumatology
– notice: Copyright © 2015 by the American College of Rheumatology.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QL
7QP
7T5
7TM
7U7
C1K
H94
K9.
7X8
DOI 10.1002/art.38969
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Toxicology Abstracts
Bacteriology Abstracts (Microbiology B)
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Toxicology Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2326-5205
EndPage 655
ExternalDocumentID 3603905861
10_1002_art_38969
25417811
ART38969
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Department of Medicine
– fundername: VA Merit Award
– fundername: Umbach Professorship in Arthritis
– fundername: Nebraska Arthritis Outcomes Research Center
– fundername: CSRD VA
  grantid: I01 CX000896
– fundername: NIAMS NIH HHS
  grantid: T32 AR050942
GroupedDBID 0R~
1OC
24P
33P
3SF
4.4
52O
52U
52V
53G
5VS
AAESR
AAEVG
AAHHS
AANLZ
AAQQT
AASGY
AAWTL
AAXRX
AAZKR
ABCUV
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZFZN
AZVAB
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
DCZOG
DIK
DRFUL
DRMAN
DRSTM
EBS
EJD
EMOBN
EX3
F00
FUBAC
G-S
G.N
GODZA
HGLYW
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LUTES
LW6
LYRES
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
NF~
O66
O9-
OK1
OVD
P2W
PQQKQ
QB0
ROL
SUPJJ
SV3
TEORI
V9Y
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WVDHM
WXSBR
YCJ
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
CITATION
7QL
7QP
7T5
7TM
7U7
C1K
H94
K9.
7X8
ID FETCH-LOGICAL-c4549-71dcf316e4a058de1edaac9114c64fdb89210b8e25a55af49f16f958b57de8503
ISSN 2326-5191
IngestDate Fri Aug 16 04:51:50 EDT 2024
Thu Oct 10 22:13:40 EDT 2024
Thu Nov 21 22:33:05 EST 2024
Sat Sep 28 08:04:55 EDT 2024
Sat Aug 24 00:58:26 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License Copyright © 2015 by the American College of Rheumatology.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4549-71dcf316e4a058de1edaac9114c64fdb89210b8e25a55af49f16f958b57de8503
Notes Dr. Nicholas has received consulting fees from Ipsen Pharmaceuticals (less than $10,000).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://europepmc.org/articles/pmc5469548?pdf=render
PMID 25417811
PQID 1657842825
PQPubID 946334
PageCount 11
ParticipantIDs proquest_miscellaneous_1659765893
proquest_journals_1657842825
crossref_primary_10_1002_art_38969
pubmed_primary_25417811
wiley_primary_10_1002_art_38969_ART38969
PublicationCentury 2000
PublicationDate March 2015
PublicationDateYYYYMMDD 2015-03-01
PublicationDate_xml – month: 03
  year: 2015
  text: March 2015
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Atlanta
PublicationTitle Arthritis & rheumatology (Hoboken, N.J.)
PublicationTitleAlternate Arthritis Rheumatol
PublicationYear 2015
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2010; 34
1995; 95
1991; 1
2002; 37
2010; 14
2011; 216
1995; 38
2004; 28
2004; 4
2008; 447
2011; 35
1988; 31
2006; 116
2012; 79
2012; 32
2011; 8
2007; 13
1998; 22
2009; 12
2002; 26
2010; 49
2006; 40
2000; 31
2011; 50
2003; 3
2009; 9
2005; 7
1988; 174
2014
2007; 66
2005; 18
2001; 14
2008; 371
2007; 26
1996; 23
2005; 79
2003; 66
1998; 141
2001; 98
21428986 - Alcohol Clin Exp Res. 2011 Jun;35(6):1106-13
3358796 - Arthritis Rheum. 1988 Mar;31(3):315-24
12946435 - Int Immunopharmacol. 2003 Oct;3(10-11):1381-99
15892575 - Chem Res Toxicol. 2005 May;18(5):817-24
20659916 - Rheumatology (Oxford). 2011 Jan;50(1):101-9
25469991 - Arthritis Rheumatol. 2015 Mar;67(3):604-8
11870872 - Glia. 2002 Mar 15;37(4):328-36
15608611 - Alcohol Clin Exp Res. 2004 Dec;28(12):1931-8
15899032 - Arthritis Res Ther. 2005;7(3):R458-67
15182728 - Int Immunopharmacol. 2004 Jul;4(7):885-99
20696236 - Free Radic Biol Med. 2010 Nov 30;49(10):1480-6
9863543 - Atherosclerosis. 1998 Nov;141(1):107-16
17854135 - World J Gastroenterol. 2007 Oct 7;13(37):4938-46
11964554 - Alcohol Clin Exp Res. 2002 Feb;26(2):158-64
17090422 - Free Radic Res. 2006 Dec;40(12):1335-8
21284345 - Eur Rev Med Pharmacol Sci. 2010 Nov;14(11):959-67
9835288 - Alcohol Clin Exp Res. 1998 Nov;22(8):1731-9
22366145 - Joint Bone Spine. 2012 Oct;79(5):431-6
21644045 - Rheumatol Int. 2012 Aug;32(8):2377-82
8666344 - Hepatology. 1996 Apr;23(4):872-80
24297382 - Ann Rheum Dis. 2015 Mar;74(3):579-86
7769103 - J Clin Invest. 1995 Jun;95(6):2611-9
21601309 - Immunobiology. 2011 Sep;216(9):1010-7
10733543 - Hepatology. 2000 Apr;31(4):878-84
20374313 - Int J Rheum Dis. 2009 Apr;12(1):29-33
16585962 - J Clin Invest. 2006 Apr;116(4):961-73
16202982 - Biochem Pharmacol. 2005 Nov 25;70(11):1593-600
21326956 - Int J Med Sci. 2011 Feb 09;8(2):139-47
16901957 - Ann Rheum Dis. 2007 Jun;66(6):712-9
18848647 - Int Immunopharmacol. 2009 Jan;9(1):38-42
18402766 - Biochem Biophys Res Commun. 2008 Jun 20;371(1):28-32
20860619 - Alcohol Clin Exp Res. 2010 Dec;34(12):2126-36
11821659 - Alcohol Clin Exp Res. 2002 Jan;26(1):94-106
18369923 - Methods Mol Biol. 2008;447:235-57
11453728 - Chem Res Toxicol. 2001 Jul;14(7):822-32
11309499 - Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
1845549 - Alcohol Alcohol Suppl. 1991;1:271-6
3239753 - Anal Biochem. 1988 Nov 1;174(2):512-21
12963492 - Biochem Pharmacol. 2003 Sep 15;66(6):1045-54
16565896 - Clin Rheumatol. 2007 Jan;26(1):64-8
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_14_1
e_1_2_7_42_1
Desai PB (e_1_2_7_12_1) 2010; 14
e_1_2_7_13_1
Tuma DJ (e_1_2_7_11_1) 1991; 1
e_1_2_7_10_1
e_1_2_7_26_1
e_1_2_7_27_1
e_1_2_7_28_1
e_1_2_7_29_1
Anderson DR (e_1_2_7_37_1) 2012; 32
e_1_2_7_30_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_23_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_20_1
e_1_2_7_36_1
Wagner CA (e_1_2_7_33_1) 2014
e_1_2_7_38_1
e_1_2_7_39_1
References_xml – volume: 49
  start-page: 1480
  year: 2010
  end-page: 6
  article-title: Malondialdehyde‐acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis
  publication-title: Free Radic Biol Med
– volume: 35
  start-page: 1106
  year: 2011
  end-page: 13
  article-title: Hybrid malondialdehyde and acetaldehyde protein adducts form in the lungs of mice exposed to alcohol and cigarette smoke
  publication-title: Alcohol Clin Exp Res
– volume: 13
  start-page: 4938
  year: 2007
  end-page: 46
  article-title: Immunological response in alcoholic liver disease
  publication-title: World J Gastroenterol
– volume: 447
  start-page: 235
  year: 2008
  end-page: 57
  article-title: Formation and immunological properties of aldehyde‐derived protein adducts following alcohol consumption
  publication-title: Methods Mol Biol
– volume: 1
  start-page: 271
  issue: Suppl
  year: 1991
  end-page: 6
  article-title: The chemistry of acetaldehyde‐protein adducts
  publication-title: Alcohol Alcohol
– volume: 79
  start-page: 431
  year: 2012
  end-page: 6
  article-title: Citrullination under physiological and pathological conditions
  publication-title: Joint Bone Spine
– volume: 4
  start-page: 885
  year: 2004
  end-page: 99
  article-title: Malondialdehyde‐acetaldehyde haptenated protein binds macrophage scavenger receptor(s) and induces lysosomal damage
  publication-title: Int Immunopharmacol
– volume: 31
  start-page: 315
  year: 1988
  end-page: 24
  article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
  publication-title: Arthritis Rheum
– volume: 66
  start-page: 1045
  year: 2003
  end-page: 54
  article-title: Chronic ethanol consumption impairs receptor‐mediated endocytosis of MAA‐modified albumin by liver endothelial cells
  publication-title: Biochem Pharmacol
– volume: 66
  start-page: 712
  year: 2007
  end-page: 9
  article-title: Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti‐citrulline autoreactivity is associated with up regulation of proinflammatory cytokines
  publication-title: Ann Rheum Dis
– volume: 26
  start-page: 158
  year: 2002
  end-page: 64
  article-title: In vitro exposure to malondialdehyde‐acetaldehyde adducted protein inhibits cell proliferation and viability
  publication-title: Alcohol Clin Exp Res
– volume: 40
  start-page: 1335
  year: 2006
  end-page: 8
  article-title: Lipofuscin‐like fluorophores originated from malondialdehyde
  publication-title: Free Radic Res
– volume: 22
  start-page: 1731
  year: 1998
  end-page: 9
  article-title: Soluble proteins modified with acetaldehyde and malondialdehyde are immunogenic in the absence of adjuvant
  publication-title: Alcohol Clin Exp Res
– volume: 9
  start-page: 38
  year: 2009
  end-page: 42
  article-title: Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis
  publication-title: Int Immunopharmacol
– volume: 371
  start-page: 28
  year: 2008
  end-page: 32
  article-title: Site‐specific modification of positively‐charged surfaces on human serum albumin by malondialdehyde
  publication-title: Biochem Biophys Res Commun
– volume: 31
  start-page: 878
  year: 2000
  end-page: 84
  article-title: Detection of circulating antibodies against malondialdehyde‐acetaldehyde adducts in patients with alcohol‐induced liver disease
  publication-title: Hepatology
– volume: 14
  start-page: 822
  year: 2001
  end-page: 32
  article-title: Elucidation of reaction scheme describing malondialdehyde‐acetaldehyde‐protein adduct formation
  publication-title: Chem Res Toxicol
– volume: 34
  start-page: 2126
  year: 2010
  end-page: 36
  article-title: Autoimmune hepatitis induced by syngeneic liver cytosolic proteins biotransformed by alcohol metabolites
  publication-title: Alcohol Clin Exp Res
– volume: 32
  start-page: A303
  issue: Suppl
  year: 2012
  article-title: Differentiating normal coronary arteries, stable atheromatous lesions and unstable atheromatous lesions: MAA‐protein adducts and anti‐MAA antibodies isotypes in patients with atherosclerotic disease and acute myocardial infarction
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 26
  start-page: 94
  year: 2002
  end-page: 106
  article-title: Adduction of soluble proteins with malondialdehyde‐acetaldehyde (MAA) induces antibody production and enhances T‐cell proliferation
  publication-title: Alcohol Clin Exp Res
– volume: 12
  start-page: 29
  year: 2009
  end-page: 33
  article-title: Status of oxidative stress in rheumatoid arthritis
  publication-title: Int J Rheum Dis
– volume: 141
  start-page: 107
  year: 1998
  end-page: 16
  article-title: Association of malondialdehyde‐acetaldehyde (MAA) adducted proteins with atherosclerotic‐induced vascular inflammatory injury
  publication-title: Atherosclerosis
– volume: 95
  start-page: 2611
  year: 1995
  end-page: 9
  article-title: Malondialdehyde‐modified low density lipoproteins in patients with atherosclerotic disease
  publication-title: J Clin Invest
– volume: 14
  start-page: 959
  year: 2010
  end-page: 67
  article-title: Oxidative stress and enzymatic antioxidant status in rheumatoid arthritis: a case control study
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 18
  start-page: 817
  year: 2005
  end-page: 24
  article-title: Aldehydes in cigarette smoke react with the lipid peroxidation product malonaldehyde to form fluorescent protein adducts on lysines
  publication-title: Chem Res Toxicol
– volume: 8
  start-page: 139
  year: 2011
  end-page: 47
  article-title: Relationship between anti‐CCP antibodies and oxidant and anti‐oxidant activity in patients with rheumatoid arthritis
  publication-title: Int J Med Sci
– volume: 79
  start-page: 1593
  year: 2005
  end-page: 600
  article-title: Rat sinusoidal liver endothelial cells (SECs) produce pro‐fibrotic factors in response to adducts formed from the metabolites of ethanol
  publication-title: Biochem Pharmacol
– volume: 216
  start-page: 1010
  year: 2011
  end-page: 7
  article-title: Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis
  publication-title: Immunobiology
– volume: 50
  start-page: 101
  year: 2011
  end-page: 9
  article-title: Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA Registry
  publication-title: Rheumatology (Oxford)
– volume: 23
  start-page: 872
  year: 1996
  end-page: 80
  article-title: Acetaldehyde and malondialdehyde react together to generate distinct protein adducts in the liver during long‐term ethanol administration
  publication-title: Hepatology
– volume: 26
  start-page: 64
  year: 2007
  end-page: 8
  article-title: Oxidative status in rheumatoid arthritis
  publication-title: Clin Rheumatol
– volume: 32
  start-page: 2377
  year: 2012
  end-page: 82
  article-title: A comparative analysis of serological parameters and oxidative stress in osteoarthritis and rheumatoid arthritis
  publication-title: Rheumatol Int
– volume: 174
  start-page: 512
  year: 1988
  end-page: 21
  article-title: Determination of malonaldehyde in oxidized lipids by the Hantzsch fluorometric method
  publication-title: Anal Biochem
– volume: 98
  start-page: 5116
  year: 2001
  end-page: 21
  article-title: Significance analysis of microarrays applied to the ionizing radiation response
  publication-title: Proc Natl Acad Sci U S A
– volume: 3
  start-page: 1381
  year: 2003
  end-page: 99
  article-title: T cell proliferative responses to malondialdehyde‐acetaldehyde haptenated protein are scavenger receptor mediated
  publication-title: Int Immunopharmacol
– volume: 37
  start-page: 328
  year: 2002
  end-page: 36
  article-title: Preparation of a monoclonal antibody to citrullinated epitopes: its characterization and some applications to immunohistochemistry in human brain
  publication-title: Glia
– volume: 28
  start-page: 1931
  year: 2004
  end-page: 8
  article-title: Lipopolysaccharide is a cofactor for malondialdehyde‐acetaldehyde adduct‐mediated cytokine/chemokine release by rat sinusoidal liver endothelial and Kupffer cells
  publication-title: Alcohol Clin Exp Res
– volume: 7
  start-page: R458
  year: 2005
  end-page: 67
  article-title: Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity
  publication-title: Arthritis Res Ther
– volume: 38
  start-page: 44
  year: 1995
  end-page: 8
  article-title: Modified disease activity scores that include twenty‐eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
  publication-title: Arthritis Rheum
– year: 2014
  article-title: Identification of anticitrullinated protein antibody reactivities in a subset of anti‐CCP‐negative rheumatoid arthritis: association with cigarette smoking and HLA‐DRB1 ‘shared epitope’ alleles
  publication-title: Ann Rheum Dis
– volume: 116
  start-page: 961
  year: 2006
  end-page: 73
  article-title: Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis
  publication-title: J Clin Invest
– ident: e_1_2_7_42_1
  doi: 10.3748/wjg.v13.i37.4938
– ident: e_1_2_7_6_1
  doi: 10.1172/JCI117963
– ident: e_1_2_7_23_1
  doi: 10.1093/rheumatology/keq232
– ident: e_1_2_7_38_1
  doi: 10.1016/j.bcp.2005.08.014
– ident: e_1_2_7_26_1
  doi: 10.1016/0003-2697(88)90051-6
– ident: e_1_2_7_22_1
  doi: 10.1111/j.1530-0277.2010.01309.x
– volume: 14
  start-page: 959
  year: 2010
  ident: e_1_2_7_12_1
  article-title: Oxidative stress and enzymatic antioxidant status in rheumatoid arthritis: a case control study
  publication-title: Eur Rev Med Pharmacol Sci
  contributor:
    fullname: Desai PB
– ident: e_1_2_7_36_1
  doi: 10.1111/j.1530-0277.2011.01443.x
– ident: e_1_2_7_28_1
  doi: 10.1002/hep.510230431
– ident: e_1_2_7_20_1
  doi: 10.1111/j.1530-0277.2002.tb02436.x
– ident: e_1_2_7_40_1
  doi: 10.1111/j.1530-0277.2002.tb02520.x
– ident: e_1_2_7_9_1
  doi: 10.1021/tx000222a
– ident: e_1_2_7_15_1
  doi: 10.1111/j.1756-185X.2009.01375.x
– ident: e_1_2_7_2_1
  doi: 10.1021/tx0500676
– ident: e_1_2_7_25_1
  doi: 10.1016/j.intimp.2008.09.008
– ident: e_1_2_7_32_1
  doi: 10.1136/ard.2006.054924
– year: 2014
  ident: e_1_2_7_33_1
  article-title: Identification of anticitrullinated protein antibody reactivities in a subset of anti‐CCP‐negative rheumatoid arthritis: association with cigarette smoking and HLA‐DRB1 ‘shared epitope’ alleles
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Wagner CA
– ident: e_1_2_7_39_1
  doi: 10.1016/j.intimp.2004.04.004
– ident: e_1_2_7_21_1
  doi: 10.1016/S1567-5769(03)00136-X
– ident: e_1_2_7_19_1
  doi: 10.1097/01.ALC.0000148115.90045.C5
– volume: 1
  start-page: 271
  year: 1991
  ident: e_1_2_7_11_1
  article-title: The chemistry of acetaldehyde‐protein adducts
  publication-title: Alcohol Alcohol
  contributor:
    fullname: Tuma DJ
– ident: e_1_2_7_27_1
  doi: 10.1002/glia.10039
– ident: e_1_2_7_8_1
  doi: 10.1111/j.1530-0277.1998.tb03973.x
– ident: e_1_2_7_10_1
  doi: 10.1016/j.bbrc.2008.03.140
– ident: e_1_2_7_16_1
  doi: 10.1007/s00296-011-1964-1
– ident: e_1_2_7_30_1
  doi: 10.1002/art.1780380107
– ident: e_1_2_7_31_1
  doi: 10.1172/JCI25422
– ident: e_1_2_7_41_1
  doi: 10.1016/S0006-2952(03)00416-7
– ident: e_1_2_7_29_1
  doi: 10.1186/ar1697
– ident: e_1_2_7_35_1
  doi: 10.1016/j.jbspin.2012.01.008
– ident: e_1_2_7_3_1
  doi: 10.1016/S0021-9150(98)00153-1
– ident: e_1_2_7_17_1
  doi: 10.7150/ijms.8.139
– ident: e_1_2_7_14_1
  doi: 10.1016/j.imbio.2011.04.001
– ident: e_1_2_7_5_1
  doi: 10.1053/he.2000.5373
– ident: e_1_2_7_7_1
  doi: 10.1080/10715760600902302
– ident: e_1_2_7_24_1
  doi: 10.1002/art.1780310302
– volume: 32
  start-page: A303
  year: 2012
  ident: e_1_2_7_37_1
  article-title: Differentiating normal coronary arteries, stable atheromatous lesions and unstable atheromatous lesions: MAA‐protein adducts and anti‐MAA antibodies isotypes in patients with atherosclerotic disease and acute myocardial infarction
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/atvb.32.suppl_1.A303
  contributor:
    fullname: Anderson DR
– ident: e_1_2_7_13_1
  doi: 10.1007/s10067-006-0244-z
– ident: e_1_2_7_18_1
  doi: 10.1016/j.freeradbiomed.2010.08.001
– ident: e_1_2_7_4_1
  doi: 10.1007/978-1-59745-242-7_17
– ident: e_1_2_7_34_1
  doi: 10.1073/pnas.091062498
SSID ssj0000970605
Score 2.5435302
Snippet Objective Malondialdehyde‐acetaldehyde (MAA) adducts are a product of oxidative stress associated with tolerance loss in several disease states. This study was...
Malondialdehyde-acetaldehyde (MAA) adducts are a product of oxidative stress associated with tolerance loss in several disease states. This study was...
Objective Malondialdehyde-acetaldehyde (MAA) adducts are a product of oxidative stress associated with tolerance loss in several disease states. This study was...
OBJECTIVEMalondialdehyde-acetaldehyde (MAA) adducts are a product of oxidative stress associated with tolerance loss in several disease states. This study was...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 645
SubjectTerms Acetaldehyde - immunology
Adult
Aged
Antigens
Arthritis, Rheumatoid - immunology
Autoantibodies - blood
Cross Reactions
Drug therapy
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunohistochemistry
Male
Malondialdehyde - immunology
Middle Aged
Osteoarthritis - immunology
Peptides, Cyclic - immunology
Rheumatism
Rheumatoid arthritis
Synovial Membrane - immunology
Title Malondialdehyde‐Acetaldehyde Adducts and Anti–Malondialdehyde‐Acetaldehyde Antibodies in Rheumatoid Arthritis
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.38969
https://www.ncbi.nlm.nih.gov/pubmed/25417811
https://www.proquest.com/docview/1657842825
https://search.proquest.com/docview/1659765893
Volume 67
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaqRUJcEG8CCwqIAxJKiRPbTY4Ru6uy2y4SaqXeovgRtVpI0JIelr_JH2L8yKNaKAuXKHXcOPF8GX8ez4wRegMUgIUEkyAqcBIQIXBQxJwGiicJZmUZx2YFf37OpktyuqKr0ejnwGtp2_Cx-PHbuJL_kSqUgVx1lOw_SLa7KRTAOcgXjiBhON5IxvPiS13pyA-p1ldSBZlQTfvjXSZ1Klebgjmrmk2wvzbU4LV2KdQWkM9rtQUqW2-ktt6vTeKjIY3tCg1yLl1tk80JGOu05vWFcoFcp-OBsWGx1vHszhZvQsh6a-wRSNd6BTlX_n7FKjMRONY_wMbE936OZ5r-28ZmV9pnx7oMtpYMTHtXrhvqy143Ag9kAZBP-281KItCOlTudq8PB-J4oKmZzWJ5bQSxGWlBpGOgcnYXmd0s3eef8pPlbJYvjleL3auWFbAQ4E0TPSW_FYH206PF0cezzvAXpjphETWbHrqXaDNehdH7ruFdnnRt8rM7lzJkaHEP3XWzGD-zkLyPRqp6gG7PnZ_GQ_R1H9Z8h0wfkOn_FZl-j0x_U_k9Mv0OhI_Q8uR48WEauI09AkEoSYMJlqKMMVOkgJ6SCitZFAKGXSIYKSVP0giHPFERLSgtSpKWoDZSmnA6kSqhYfwYHVR1pZ4iP6VpwWIgHKESpEwU53IiSyBcIlECBjAPvW67Mf9m87fkNlN3lENf56avPXTYdnDuPu_vOWYwmBEd2u2hV91lUL56Ra2oVL01dYDOU-D8HnpiBdO1ElGCdRi3h94aSf25-Rymrubk2f7neI7u9J_NITpoLrfqBVDihr80EPsF1XC5cw
link.rule.ids 315,782,786,27931,27932
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Malondialdehyde-Acetaldehyde+Adducts+and+Anti-Malondialdehyde-Acetaldehyde+Antibodies+in+Rheumatoid+Arthritis&rft.jtitle=Arthritis+%26+rheumatology+%28Hoboken%2C+N.J.%29&rft.au=Thiele%2C+Geoffrey+M&rft.au=Duryee%2C+Michael+J&rft.au=Anderson%2C+Daniel+R&rft.au=Klassen%2C+Lynell+W&rft.date=2015-03-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=2326-5191&rft.eissn=2326-5205&rft.volume=67&rft.issue=3&rft.spage=645&rft_id=info:doi/10.1002%2Fart.38969&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=3603905861
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-5191&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-5191&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-5191&client=summon